Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. J Natl Cancer Inst Monogr. 1975;42:101–4.

CAS  Google Scholar 

Hacker NF, Berek JS, Lagasse LD, et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol. 1983;61:413–20.

CAS  PubMed  Google Scholar 

Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170:974–9.

Article  CAS  PubMed  Google Scholar 

Farias-Eisner R, Teng F, Oliveira M, et al. The influence of tumor grade, distribution and extent of carcinomatosis in minimal residual epithelial ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol. 1994;55:108–10.

Article  CAS  PubMed  Google Scholar 

Berek JS. Complete debulking of advanced ovarian cancer. Cancer J. 1996;2:134–5.

Google Scholar 

Farias-Eisner R, Kim YB, Berek JS. Surgical management of ovarian cancer. Semin Surg Oncol. 1994;10:268–75.

Article  CAS  PubMed  Google Scholar 

Eisenkop SM, Friedman RL, Wang H-J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998;69:103–8.

Article  CAS  PubMed  Google Scholar 

Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, European Organization for Research and Treatment of Cancer- Gynaecological Cancer Group; NCIC Clinical Trials Group et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363(10):943–53

Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open label, randomised, controlled, non-inferiority trial. Lancet Oncol. 2015;386(9990):249–57.

Article  Google Scholar 

Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival Ða review of the epidemiological literature. J Ovarian Res. 2009;2:13.

Article  PubMed  PubMed Central  Google Scholar 

Gadducci A, Cosio S, Tana R, Genazzani AR. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol. 2009. https://doi.org/10.1016/j.critrevonc.2008.05.001.

Article  PubMed  Google Scholar 

Coakley FV, Westphalen AC, Hricak H, Okuno WT, Powell B. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol. 2005;96(2):301–6.

Article  PubMed  Google Scholar 

Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol. 1993;11:166–72.

Article  CAS  PubMed  Google Scholar 

Stroun M, Maurice P, Vasioukhin V, Lyautey J, Lederrey C, Lefort F, et al. The origin and mechanism of circulating DNA. Ann N Y Acad Sci. 2000;906:161–8.

Article  ADS  CAS  PubMed  Google Scholar 

Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumor DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev. 1999;18:65–73.

Article  CAS  PubMed  Google Scholar 

Cheng X, Zhang L, Chen Y, Qing C. Circulating cell-free DNA and circulating tumor cells, the “liquid biopsies” in ovarian cancer. J Ovarian Res. 2017;10:75.

Article  PubMed  PubMed Central  Google Scholar 

Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, et al. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer. 2010;116(8):1918–25.

Article  CAS  PubMed  Google Scholar 

Zachariah RR, Schmid S, Buerki N, Radpour R, Holzgreve W, Zhong X. Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors. Obstet Gynecol. 2008;112(4):843–50.

Article  CAS  PubMed  Google Scholar 

Kalavska K, Minarik T, Vlkova B, Manasova D, Kubickova M, Jurik A, Mardiak J, Sufliarsky J, Celec P. M MegoPrognostic value of various subtypes of extracellular DNA in ovarian cancer patients. J Ovarian Res. 2018;11:85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Steffensen KD, Madsen CV, Andersen RF, Waldstrom M, Adimi P, Jakobsen A. Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab. Eur J Cancer. 2014;50(15):2611–8.

Article  CAS  PubMed  Google Scholar 

No JH, Kim K, Park KH, Kim YB. Cell-free DNA level as a prognostic biomarker for epithelial ovarian cancer. Anticancer Res. 2012;32(8):3467–71.

PubMed  Google Scholar 

Mandel P, Metais P. Nuclear acids in human blood plasma. C R Seances Soc Biol Fil. 1948;142(3–4):241–3.

CAS  PubMed  Google Scholar 

Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646–50.

CAS  PubMed  Google Scholar